Anthropic has acquired Mithril Medicine, a one-person biotech whose founder, Cody Tranbarger, used Claude to run a drug program for two rare forms of muscular dystrophy. The AI company disclosed the deal in a post on October 27, a day after it filed for its Nasdaq IPO, and did not disclose the terms.
The purchase gives Anthropic, a software company that sells AI models, a drug candidate of its own. A technical report Mithril published with the announcement says Anthropic "acquired Mithril Medicine in July 2026" and now "owns the antibody program described here."
What Mithril built
Tranbarger "used Claude to organize contracts, logistics, and experiments with 11 external labs, and delegated many other aspects of Mithril's operations to Claude," Anthropic said. As a result, it said, Mithril took a possible treatment "from an idea to promising results in mice in less than 18 months." Tranbarger's own post describes Mithril as "a single operator + a bunch of Claude (+ a stellar bench of part-time consultants)," and the report says members of the Mithril team have been paid consultants or advisers.
The target is LAMA2-related congenital muscular dystrophy, a childhood disease with no disease-modifying treatment, according to the report. Mithril designed bispecific antibodies meant to restore the anchorage around muscle fibers that the missing protein normally provides. In a pilot study, mice given one version "developed about twice the peak force and grip strength of vehicle-treated mice," the report says.
The results are early. The report is marked "Not peer reviewed," and its methods section says the work "was exploratory and not conducted under Good Laboratory Practice." Anthropic said that if the candidates hold up, it expects a drug "to be ready to start clinical trials in humans as soon as late 2028," which is 24 to 26 months after the announcement.
How one person ran the labs
Mithril's experiments ran at contract research organizations (CROs), outside labs paid per study. The report breaks down one week in which, it says, a team member "working with Claude" turned a 341-page data package on 113 antibody constructs into a single plan across five CROs.
That week, Claude's first answer to a request took a median of 96 seconds, against 8.5 hours for a CRO's first reply to an email. By a SaasBuzz calculation from those medians, the labs took about 319 times as long to respond, so the pace was set by the labs and by the team's decisions, as the report itself concludes. Claude drafted 17 emails and the team sent 12, or 71%, each after the team edited it.
The report also counts mistakes. Of six errors it examined, "at least three reached a CRO in emails that we had edited and sent," including a request for less material per tube than a lab had asked for, which was corrected before any tube was filled. The report notes that this section "was compiled by Claude from its own threads and notes and therefore carries a risk of bias."
Tranbarger, who posted for six years on X as the pseudonymous biotech commentator Professor Oak, named himself and gave his reasons for joining Anthropic in a long post the same day. Bruce Booth of Atlas Venture, which Tranbarger says provided Mithril's seed money, replied to the account on X as "Cody."
Post on X by @Prof_Oak_
Surprise 1: Anthropic acquired a one-person biotech . . . Surprise 2: that person is me Surprise 3: I’m here to tell you all about it Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post …and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline ------- Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere. The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases. Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat. In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally. Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants). In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model. From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team. Why join Anthropic? Three reasons. (1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work. (2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter. (3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing. Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit. Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest). Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI. Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have. It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way. But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember... Gotta Cure 'Em All
What the deal says about Anthropic's life sciences push
Mithril follows an earlier biology deal. Anthropic's S-1 filing says that in April it "completed the acquisition of Coefficient Bio, Inc., a computational biology company, to accelerate our research in the life sciences," for 15.4 million Class A shares, part of which counts as pay for continuing employees. The same filing lists "building a molecular biology lab" among its life sciences investments. The S-1 does not name Mithril.
Date | Step | Source |
|---|---|---|
April 2026 | Buys Coefficient Bio for 15.4M shares | S-1 |
July 2026 | Buys Mithril; terms undisclosed | Mithril report |
Oct. 26 | Files S-1 for Nasdaq IPO | S-1 |
Oct. 27 | Names Mithril and six drug partners | Anthropic |
Source: Anthropic's Form S-1, Anthropic's October 27 post and Mithril's technical report.
The filing also flags the cost of that shift. Programs including "our life sciences research program, which involves operating laboratory facilities," require Anthropic "to engage in activities outside our historical experience as a software and research organization," the risk factors say. Owning a drug program adds to that exposure at a company that, its S-1 says, generates revenue "as customers use Claude through our platform and applications" (SaasBuzz covered the filing).
Anthropic's own explanation ties the programs back to that business. It said the work helps it "better understand the strengths and limitations of our models," that the programs "can serve as case studies for the wider life sciences community," and that "we need to work with many more biotechnology firms and integrate Claude more deeply into their development processes." The S-1 makes the same pitch, saying Claude "is used in drug discovery and development by our customers, our biotechnology partners, and our own researchers."
The six partners Anthropic named alongside Mithril are BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group.
For software buyers, the Mithril report is a detailed public account of how much of a lab program Claude handled and where people still decided: in the week it details, every Claude draft that went out was edited first, and the labs set the pace. Anthropic said it plans "to scale this work up substantially from here," and Tranbarger is continuing the research at Anthropic and plans to start several new programs, the company said.
